Publication

Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Saad, F.
; 
Armstrong, A. J.
; 
Thiery-Vuillemin, A.
; 
Oya, M.
; 
Shore, N. D.
; 
Procopio, G.
; 
Arslan, C.
; 
Mehra, N.
; 
Parnis, F.
; 
Brown, E.
... show 9 more
Citations
Altmetric:
Abstract
Authors
Saad, F.
Armstrong, A. J.
Thiery-Vuillemin, A.
Oya, M.
Shore, N. D.
Procopio, G.
Arslan, C.
Mehra, N.
Parnis, F.
Brown, E.
Schlurmann, F. C.
Joung, J. Y.
Sugimoto, M.
Sartor, O.
Liu, Y. Z.
Poehlein, C. H.
Desai, C.
Del Rosario, P. M. D.
Clarke, Noel W
Affiliation
Department Of Urology, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, H2X 3J4
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, et al. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Sep;33(7):S1160-S. PubMed PMID: WOS:000866211601614.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625972
Embedded videos